Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY PLUARD

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1396761698
CMS profile
1199860
Location
KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$88,614.05

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Seagen Inc. $26,176.64 15
Gilead Sciences, Inc. $20,468.96 15
AstraZeneca Pharmaceuticals LP $11,731.63 7
PFIZER INC. $8,610.56 4
Daiichi Sankyo Inc. $7,940.47 6
Novartis Pharmaceuticals Corporation $7,343.75 4
Genentech USA, Inc. $2,895.04 2
Amgen Inc. $1,947.00 1
MACROGENICS, INC. $1,500.00 1

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY PLUARD

NPI 1396761698 · CMS profile ID 1199860

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396761698?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY PLUARD, NPI 1396761698, CMS profile ID 1199860. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396761698?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TIMOTHY PLUARD, NPI 1396761698, CMS profile ID 1199860. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396761698?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TIMOTHY PLUARD, NPI 1396761698, CMS profile ID 1199860, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1396761698?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $88,614.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $116.6304/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829853907 CMS
AstraZeneca Pharmaceuticals LP $1,370.0004/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829397137 CMS
MACROGENICS, INC. $1,500.0003/17/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833897731 CMS
Seagen Inc. $460.0002/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832157215 CMS
Daiichi Sankyo Inc. $685.0001/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836241185 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $83,448.81 81
PY2020 $39,175.02 28
PY2021 $88,614.05 55
PY2022 $146,334.03 98
PY2023 $154,369.25 101
PY2024 $86,053.13 63
PY2025 $65,572.30 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,870,632.89 305
PY2024 Recipient $10,990.29 6
PY2024 Principal investigator $3,849,817.95 152
PY2023 Recipient $12,584.62 5
PY2023 Principal investigator $1,596,615.90 197
PY2022 Recipient $9,812.00 7
PY2022 Principal investigator $1,911,751.37 193
PY2021 Recipient $3,263.00 6
PY2021 Principal investigator $1,186,628.03 162
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $1,057,802.35 127
PY2019 Principal investigator $597,645.46 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

305 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $153,392.40 12/31/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer No dispute reported 06/30/2026 1232923296
Principal investigator 1 PFIZER INC. $10,999.17 12/31/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709114
Principal investigator 1 PFIZER INC. $76,580.00 12/31/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709298
Principal investigator 1 PFIZER INC. $7,013.72 12/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709104
Principal investigator 1 PFIZER INC. $2,491.06 12/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709187
Principal investigator 1 PFIZER INC. $2,533.08 12/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228709284
Principal investigator 1 PFIZER INC. $4,867.56 12/29/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708262
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $7,892.60 12/29/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753638
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $6,642.22 12/29/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753640
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $4,050.00 12/29/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753642
Principal investigator 1 PFIZER INC. $19,206.12 12/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709102
Principal investigator 1 PFIZER INC. $45.00 12/15/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708848
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,485.47 12/15/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753650
Principal investigator 1 PFIZER INC. $37,736.16 12/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709286
Principal investigator 1 PFIZER INC. $8,940.48 12/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709462
Principal investigator 1 PFIZER INC. $7.50 12/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708452
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,100.00 12/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment No dispute reported 06/30/2026 1236000270
Principal investigator 1 PFIZER INC. $45.00 12/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708366
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $8,705.82 12/01/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753636
Principal investigator 1 PFIZER INC. $11,967.80 11/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709460
Principal investigator 1 PFIZER INC. $1,862.04 11/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228709324
Principal investigator 1 PFIZER INC. $7.50 11/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707996
Principal investigator 1 PFIZER INC. $21,998.34 11/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708014
Principal investigator 1 PFIZER INC. $32,820.00 11/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708194
Principal investigator 1 PFIZER INC. $5,470.00 11/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708564
Principal investigator 1 PFIZER INC. $10,999.17 11/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709296
Principal investigator 1 PFIZER INC. $32,820.00 11/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708378
Principal investigator 1 PFIZER INC. $54,995.85 11/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708840
Principal investigator 1 PFIZER INC. $4,867.56 11/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709280
Principal investigator 1 PFIZER INC. $10,386.60 11/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708596
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,495.72 11/14/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753648
Principal investigator 1 PFIZER INC. $15,535.52 11/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708000
Principal investigator 1 PFIZER INC. $14,667.84 11/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709383
Principal investigator 1 PFIZER INC. $21,998.34 11/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708116
Principal investigator 1 PFIZER INC. $21,880.00 11/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708196
Principal investigator 1 PFIZER INC. $5,470.00 11/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708566
Principal investigator 1 PFIZER INC. $10,999.17 11/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708650
Principal investigator 1 PFIZER INC. $54,995.85 11/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708755
Principal investigator 1 PFIZER INC. $32,820.00 11/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709116
Principal investigator 1 PFIZER INC. $30.00 11/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709183
Principal investigator 1 PFIZER INC. $114,601.20 11/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709282
Principal investigator 1 PFIZER INC. $20,819.26 11/04/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709381
Principal investigator 1 PFIZER INC. $3,982.48 10/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708374
Principal investigator 1 PFIZER INC. $8,304.72 10/29/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708042
Principal investigator 1 PFIZER INC. $8,304.72 10/29/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709240
Principal investigator 1 PFIZER INC. $87,520.00 10/27/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708182
Principal investigator 1 PFIZER INC. $10,999.17 10/27/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708842
Principal investigator 1 PFIZER INC. $120,990.87 10/27/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709014
Principal investigator 1 PFIZER INC. $9,005.00 10/27/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228709243
Principal investigator 1 PFIZER INC. $7.50 10/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708176
Principal investigator 1 PFIZER INC. $3,189.12 10/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708372
Principal investigator 1 Exelixis Inc. $319.41 10/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377930
Principal investigator 1 Exelixis Inc. $319.41 10/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377932
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.00 10/22/2025 Non-covered Recipient Entity
SAINT LUKES HOSPITAL OF KANSAS CITY
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1192135346
Principal investigator 1 PFIZER INC. $87,520.00 10/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708114
Principal investigator 1 PFIZER INC. $120,990.87 10/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708560
Principal investigator 1 PFIZER INC. $10,999.17 10/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708759
Principal investigator 1 PFIZER INC. $4,867.56 10/20/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709018
Principal investigator 1 PFIZER INC. $2,533.08 10/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228707998
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $7,086.79 10/15/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753646
Principal investigator 1 PFIZER INC. $27,293.64 10/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708178
Principal investigator 1 PFIZER INC. $864.66 10/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709245
Principal investigator 1 PFIZER INC. $336.60 10/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228709421
Principal investigator 1 PFIZER INC. $17,855.29 10/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709423
Principal investigator 1 PFIZER INC. $95,501.00 10/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709012
Principal investigator 1 PFIZER INC. $45,840.45 10/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709016
Principal investigator 1 PFIZER INC. $22.50 10/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709100
Principal investigator 1 PFIZER INC. $16,376.14 10/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708180
Principal investigator 1 PFIZER INC. $8,165.04 10/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709458
Principal investigator 1 PFIZER INC. $4,082.52 10/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709189
Principal investigator 1 PFIZER INC. $8,304.72 10/06/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708040
Principal investigator 1 PFIZER INC. $12,709.20 10/06/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709425
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $89.38 10/01/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735936
Principal investigator 1 PFIZER INC. $5,750.00 09/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708794
Principal investigator 1 PFIZER INC. $7,152.60 09/29/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708680
Principal investigator 1 PFIZER INC. $7.50 09/26/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709185
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 09/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735928
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $200.00 09/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735930
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735932
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 09/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735934
Principal investigator 1 PFIZER INC. $131,990.04 09/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708274
Principal investigator 1 PFIZER INC. $10,940.00 09/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708376
Principal investigator 1 PFIZER INC. $1,622.52 09/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709456
Principal investigator 1 PFIZER INC. $10,940.00 09/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708562
Principal investigator 1 PFIZER INC. $2,491.06 09/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708709
Principal investigator 1 PFIZER INC. $19,166.78 09/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708832
Principal investigator 1 PFIZER INC. $131,990.04 09/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709112
Principal investigator 1 PFIZER INC. $22.50 09/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708936
Principal investigator 1 Exelixis Inc. $350.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377874
Principal investigator 1 Exelixis Inc. $1,200.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377884
Principal investigator 1 Exelixis Inc. $1,000.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377898
Principal investigator 1 Exelixis Inc. $550.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377910
Principal investigator 1 Exelixis Inc. $3,200.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377914
Principal investigator 1 Exelixis Inc. $2,200.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377920
Principal investigator 1 Exelixis Inc. $550.00 09/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377922
Principal investigator 1 PFIZER INC. $43,760.00 09/16/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708844
Principal investigator 1 PFIZER INC. $43,760.00 09/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708186
Principal investigator 1 PFIZER INC. $13,347.60 09/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708713
Principal investigator 1 PFIZER INC. $15.00 09/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708368
Principal investigator 1 PFIZER INC. $32,820.00 09/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708016
Principal investigator 1 PFIZER INC. $10,999.17 09/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708184
Principal investigator 1 PFIZER INC. $32,997.51 09/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708198
Principal investigator 1 PFIZER INC. $5,470.00 09/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708763
Principal investigator 1 PFIZER INC. $124,800.28 09/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708917
Principal investigator 1 Exelixis Inc. $455.00 09/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377892
Principal investigator 1 Exelixis Inc. $62.40 09/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377896
Principal investigator 1 Exelixis Inc. $2,232.10 09/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377900
Principal investigator 1 Exelixis Inc. $1,904.50 09/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377906
Principal investigator 1 Exelixis Inc. $3,142.10 09/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377908
Principal investigator 1 Exelixis Inc. $455.00 09/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377918
Principal investigator 1 PFIZER INC. $2,968.68 09/06/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708536
Principal investigator 1 PFIZER INC. $15.00 09/02/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709098
Principal investigator 1 PFIZER INC. $7.50 08/29/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708938
Principal investigator 1 Exelixis Inc. $5,465.07 08/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377912
Principal investigator 1 PFIZER INC. $1,286.40 08/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708574
Principal investigator 1 Exelixis Inc. $52.52 08/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377872
Principal investigator 1 Exelixis Inc. $207.61 08/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377886
Principal investigator 1 Exelixis Inc. $52.52 08/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377888
Principal investigator 1 Exelixis Inc. $159.91 08/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377904
Principal investigator 1 Exelixis Inc. $11.71 08/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377916
Principal investigator 1 PFIZER INC. $15.00 08/15/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708450
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $294.69 08/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735916
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735918
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,250.00 08/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735920
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 08/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735922
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 08/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735924
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 08/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735926
Principal investigator 1 PFIZER INC. $10,999.17 08/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709199
Principal investigator 1 PFIZER INC. $10,999.17 08/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709288
Principal investigator 1 PFIZER INC. $87,993.36 08/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708382
Principal investigator 1 PFIZER INC. $1,867.80 08/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708422
Principal investigator 1 PFIZER INC. $2,796.58 08/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708018
Principal investigator 1 PFIZER INC. $87,993.36 08/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709197
Principal investigator 1 PFIZER INC. $21,998.34 08/05/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708380
Principal investigator 1 PFIZER INC. $2,533.08 08/05/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708576
Principal investigator 1 PFIZER INC. $21,998.34 08/05/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709118
Principal investigator 1 PFIZER INC. $10,041.60 08/04/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708424
Principal investigator 1 PFIZER INC. $834.82 08/04/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708598
Principal investigator 1 PFIZER INC. $7.50 08/01/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708846
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 07/31/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753634
Principal investigator 1 PFIZER INC. $3,245.04 07/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709010
Principal investigator 1 PFIZER INC. $4,991.42 07/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709175
Principal investigator 1 PFIZER INC. $3,245.04 07/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707994
Principal investigator 1 PFIZER INC. $15.00 07/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709377
Principal investigator 1 Exelixis Inc. $223.60 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377864
Principal investigator 1 Exelixis Inc. $3,142.10 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377866
Principal investigator 1 Exelixis Inc. $127.40 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377868
Principal investigator 1 Exelixis Inc. $507.00 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377870
Principal investigator 1 Exelixis Inc. $1,904.50 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377876
Principal investigator 1 Exelixis Inc. $2,232.10 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377880
Principal investigator 1 Exelixis Inc. $455.00 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377882
Principal investigator 1 Exelixis Inc. $2,952.30 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377890
Principal investigator 1 Exelixis Inc. $455.00 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377894
Principal investigator 1 Exelixis Inc. $455.00 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377902
Principal investigator 1 Exelixis Inc. $62.40 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377924
Principal investigator 1 Exelixis Inc. $278.20 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377928
Principal investigator 1 PFIZER INC. $8,304.72 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708134
Principal investigator 1 PFIZER INC. $1,066.56 07/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708212
Principal investigator 1 PFIZER INC. $7.50 07/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709379
Principal investigator 1 PFIZER INC. $9,800.76 07/15/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709172
Principal investigator 1 PFIZER INC. $7.50 07/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708174
Principal investigator 1 Exelixis Inc. $579.01 07/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377878
Principal investigator 1 Exelixis Inc. $15.04 07/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377926
Principal investigator 1 PFIZER INC. $2,171.52 07/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708214
Principal investigator 1 PFIZER INC. $6,490.08 07/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708260
Principal investigator 1 PFIZER INC. $7.50 07/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709375
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,200.00 07/03/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233735914
Principal investigator 1 PFIZER INC. $1,306.86 06/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708132
Principal investigator 1 PFIZER INC. $864.66 06/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708304
Principal investigator 1 PFIZER INC. $6,250.00 06/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709134
Principal investigator 1 PFIZER INC. $2,356.44 06/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709316
Principal investigator 1 PFIZER INC. $24,250.00 06/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709089
Principal investigator 1 PFIZER INC. $9,250.00 06/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709136
Principal investigator 1 PFIZER INC. $9,750.00 06/23/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709138
Principal investigator 1 PFIZER INC. $5,470.00 06/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708540
Principal investigator 1 PFIZER INC. $10,999.17 06/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708624
Principal investigator 1 PFIZER INC. $1,622.51 06/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708172
Principal investigator 1 PFIZER INC. $32,997.51 06/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708264
Principal investigator 1 PFIZER INC. $32,820.00 06/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708266
Principal investigator 1 PFIZER INC. $1,102.20 06/16/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708302
Principal investigator 1 PFIZER INC. $8,597.84 06/16/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709314
Principal investigator 1 PFIZER INC. $7.50 06/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708402
Principal investigator 1 PFIZER INC. $2,533.08 06/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228709087
Principal investigator 1 PFIZER INC. $9,005.00 06/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708130
Principal investigator 1 PFIZER INC. $7.50 06/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709369
Principal investigator 1 PFIZER INC. $1,622.51 06/09/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709371
Principal investigator 1 GlaxoSmithKline, LLC. $3,850.00 06/06/2025 Non-covered Recipient Entity
SAINT LUKES HOSPITAL OF KANSAS CITY
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN No dispute reported 06/30/2026 1192135353
Principal investigator 1 PFIZER INC. $6,490.04 06/02/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708404
Principal investigator 1 PFIZER INC. $11,416.20 06/02/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709132
Principal investigator 1 PFIZER INC. $15.00 05/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708482
Principal investigator 1 PFIZER INC. $57,300.60 05/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228709452
Principal investigator 1 PFIZER INC. $1,573.44 05/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708784
Principal investigator 1 PFIZER INC. $2,750.00 05/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708630
Principal investigator 1 PFIZER INC. $1,550.81 05/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709312
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $27,750.00 05/14/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
ALI-1201 No dispute reported 06/30/2026 1251753644
Principal investigator 1 PFIZER INC. $2,533.08 05/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708632
Principal investigator 1 PFIZER INC. $10,940.00 05/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708740
Principal investigator 1 PFIZER INC. $43,996.68 05/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708934
Principal investigator 1 PFIZER INC. $1,622.51 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708446
Principal investigator 1 PFIZER INC. $7.50 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708480
Principal investigator 1 PFIZER INC. $43,996.68 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708634
Principal investigator 1 PFIZER INC. $10,940.00 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708636
Principal investigator 1 PFIZER INC. $9,593.06 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708782
Principal investigator 1 PFIZER INC. $2,170.80 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709230
Principal investigator 1 PFIZER INC. $7,152.60 05/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709232
Principal investigator 1 Exelixis Inc. $2,402.01 05/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377840
Principal investigator 1 Exelixis Inc. $2,402.01 05/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377842
Principal investigator 1 PFIZER INC. $6,490.04 05/05/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709373
Principal investigator 1 PFIZER INC. $68,306.26 05/03/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708546
Principal investigator 1 PFIZER INC. $20,924.64 04/30/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708544
Principal investigator 1 Exelixis Inc. $90.09 04/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377836
Principal investigator 1 Exelixis Inc. $266.89 04/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377838
Principal investigator 1 Exelixis Inc. $238.29 04/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377846
Principal investigator 1 Exelixis Inc. $431.21 04/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377852
Principal investigator 1 Exelixis Inc. $266.89 04/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377854
Principal investigator 1 PFIZER INC. $5,470.00 04/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708548
Principal investigator 1 PFIZER INC. $43,760.00 04/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708456
Principal investigator 1 PFIZER INC. $7,000.00 04/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708668
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,869.90 04/16/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190296763
Principal investigator 1 PFIZER INC. $3,245.02 04/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707990
Principal investigator 1 PFIZER INC. $7.50 04/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708254
Principal investigator 1 PFIZER INC. $16,609.44 04/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708664
Principal investigator 1 PFIZER INC. $1,346.40 04/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708874
Principal investigator 1 Exelixis Inc. $3,142.10 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377844
Principal investigator 1 Exelixis Inc. $455.00 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377848
Principal investigator 1 Exelixis Inc. $127.40 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377850
Principal investigator 1 Exelixis Inc. $507.00 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377856
Principal investigator 1 Exelixis Inc. $278.20 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377858
Principal investigator 1 Exelixis Inc. $1,904.50 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377860
Principal investigator 1 Exelixis Inc. $223.60 04/11/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377862
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,097.16 04/08/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A pilot and biomarker study of fulvestrant, alpelisib and dapaglifozin in hormone receptor positive, HER2 negative metastatic breast cancer No dispute reported 06/30/2026 1190296758
Principal investigator 1 PFIZER INC. $7,781.17 04/07/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708666
Principal investigator 1 PFIZER INC. $13,053.48 04/05/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708542
Principal investigator 1 PFIZER INC. $9,012.00 03/31/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228709057
Principal investigator 1 PFIZER INC. $10,999.17 03/26/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708736
Principal investigator 1 Exelixis Inc. $3,880.89 03/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377804
Principal investigator 1 Exelixis Inc. $810.81 03/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377820
Principal investigator 1 Exelixis Inc. $2,144.61 03/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377828
Principal investigator 1 PFIZER INC. $43,996.68 03/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708268
Principal investigator 1 PFIZER INC. $6,490.04 03/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708258
Principal investigator 1 PFIZER INC. $8,139.12 03/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708626
Principal investigator 1 PFIZER INC. $20,364.96 03/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708828
Principal investigator 1 PFIZER INC. $7.50 03/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708362
Principal investigator 1 PFIZER INC. $2,533.08 03/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708628
Principal investigator 1 PFIZER INC. $11,763.86 03/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708678
Principal investigator 1 PFIZER INC. $1,407.36 03/10/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708884
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28,550.00 03/03/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233735912
Principal investigator 1 PFIZER INC. $3,248.52 03/01/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708830
Principal investigator 1 PFIZER INC. $5,470.00 02/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708729
Principal investigator 1 PFIZER INC. $10,999.17 02/25/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708932
Principal investigator 1 PFIZER INC. $10,940.00 02/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708370
Principal investigator 1 PFIZER INC. $54,995.85 02/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708454
Principal investigator 1 PFIZER INC. $8,033.36 02/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708886
Principal investigator 1 Exelixis Inc. $392.21 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377786
Principal investigator 1 Exelixis Inc. $99.84 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377788
Principal investigator 1 Exelixis Inc. $2,232.36 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377790
Principal investigator 1 Exelixis Inc. $248.04 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377792
Principal investigator 1 Exelixis Inc. $3,529.89 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377794
Principal investigator 1 Exelixis Inc. $99.84 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377796
Principal investigator 1 Exelixis Inc. $248.04 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377798
Principal investigator 1 Exelixis Inc. $5,465.07 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377800
Principal investigator 1 Exelixis Inc. $2,232.36 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377802
Principal investigator 1 Exelixis Inc. $3,349.71 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377806
Principal investigator 1 Exelixis Inc. $247.39 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377808
Principal investigator 1 Exelixis Inc. $372.19 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377810
Principal investigator 1 Exelixis Inc. $607.23 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377812
Principal investigator 1 Exelixis Inc. $2,226.51 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377814
Principal investigator 1 Exelixis Inc. $3,529.89 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377816
Principal investigator 1 Exelixis Inc. $431.21 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377818
Principal investigator 1 Exelixis Inc. $3,880.89 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377822
Principal investigator 1 Exelixis Inc. $898.56 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377824
Principal investigator 1 Exelixis Inc. $39.78 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377826
Principal investigator 1 Exelixis Inc. $392.21 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377830
Principal investigator 1 Exelixis Inc. $358.02 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377832
Principal investigator 1 Exelixis Inc. $898.56 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222377834
Principal investigator 1 PFIZER INC. $12,980.08 02/19/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708170
Principal investigator 1 PFIZER INC. $6,197.40 02/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708676
Principal investigator 1 PFIZER INC. $9,005.00 02/18/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708882
Principal investigator 1 PFIZER INC. $9,735.06 02/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708364
Principal investigator 1 PFIZER INC. $7.50 02/17/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708448
Principal investigator 1 PFIZER INC. $29,711.88 02/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708538
Principal investigator 1 PFIZER INC. $21,689.84 02/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708919
Principal investigator 1 PFIZER INC. $5,470.00 02/13/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708928
Principal investigator 1 PFIZER INC. $10,940.00 02/12/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708458
Principal investigator 1 PFIZER INC. $12,709.19 02/03/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228708216
Principal investigator 1 PFIZER INC. $26,437.13 02/03/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228709055
Principal investigator 1 PFIZER INC. $7,152.60 02/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228830850
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 01/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735900
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 01/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735902
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735904
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 01/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735906
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,250.00 01/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735908
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/28/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant No dispute reported 06/30/2026 1233735910
Principal investigator 1 PFIZER INC. $3,248.52 01/24/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709000
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,200.00 01/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185539473
Principal investigator 1 PFIZER INC. $10,999.17 01/22/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708550
Principal investigator 1 PFIZER INC. $43,996.68 01/21/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228708638
Principal investigator 1 PFIZER INC. $325.00 01/20/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228707992
Principal investigator 1 PFIZER INC. $1,950.00 01/20/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708168
Principal investigator 1 PFIZER INC. $7.50 01/20/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708256
Principal investigator 1 PFIZER INC. $10,940.00 01/15/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708930
Principal investigator 1 PFIZER INC. $10,940.00 01/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228708552
Principal investigator 1 PFIZER INC. $2,533.08 01/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228708998
Principal investigator 1 PFIZER INC. $19,966.32 01/14/2025 Covered Recipient Teaching Hospital
Saint Lukes Hospital Of Kansas City
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709002
Principal investigator 1 Eli Lilly and Company $94,809.33 01/02/2025 Covered Recipient Teaching Hospital
SAINT LUKES HOSPITAL OF KANSAS CITY
Not supplied No dispute reported 06/30/2026 1187873383